Navigation Links
BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement
Date:8/17/2009

BOTHELL, Wash., Aug. 17 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading manufacturer and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has entered into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based in Vancouver, Canada. STEMCELL Technologies, a member of the StemCell Group of companies, is a leading provider of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research.

Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to now have our products represented and distributed throughout the world by STEMCELL Technologies and their sub-distributor partners. Their MethoCult(R) reagent systems have become worldwide standards and we look forward to their distribution network's ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption."

Allen Eaves M.D., Ph.D., founder of STEMCELL Technologies and Chairman of the StemCell Group, commented on the addition of BioLife's products to their reagents and media portfolio by stating, "Our interest in BioLife Solutions has grown as we've seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery. We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world."

About BioLife Solutions

BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryop
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
2. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
3. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
4. BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter
5. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
6. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
7. BioLife Solutions Granted European Biopreservation Patent
8. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
9. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
10. BioLife Solutions Credit Facility Increased to $9 Million
11. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... company,focused on commercializing proprietary product candidates for ... announced that the U.S. Food and,Drug Administration ... ANX-510,or CoFactor(R) injection, which is currently being ...
... Drug Application in the Fourth ... ... positive results from a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal ... chronic non-cancer pain,conditions. The study achieved statistical significance on the primary,endpoint. Results ...
... Presentations on the Topic of Drug Repurposing and ... Indian Clinical ... Inc., an,oncology-focused, clinical-stage biopharmaceutical company, announced today,that Chief Executive Officer, ... present at the 234th American Chemical,Society National Meeting on Sunday, ...
Cached Biology Technology:ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Putnam Valley, NY. (June 26 , 2012) Researchers ... transplanting two varieties of stem cells into mouse cochlea ... cells and mouse embryonic stem (ES) cells demonstrate similar ... risk of tumor growth associated with transplanting iPS cells ...
... NEVERS, France, June 26, 2012 Polar ( ... assessment technology, together with LOOK , the inventor and ... of the first clipless cycling pedals to measure cycling power ... left/right balance and power output, and send the data directly ...
... discovered a new flu-fighting role for a well-known component ... cellular biology in the UGA Franklin College of Arts ... cell-signaling protein known as IL-15 to mice infected with ... times. "We gave the IL-15 intranasally and ...
Cached Biology News:Stem cell transplantation into mouse cochlea may impact future hearing loss therapies 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 3Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 4UGA study reveals flu-fighting role for well-known immune component 2
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
...
Biology Products: